TY - JOUR
T1 - Effect of XELOX on functional ability among elderly patients with metastatic colorectal cancer
T2 - Results from the FNCLCC/GERICO 02 phase II study
AU - Rousseau, Frédérique
AU - Bugat, Roland
AU - Ducreux, Michel
AU - Cvitkovic, Frédérique
AU - Carola, Elisabeth
AU - Gisselbrecht, Mathilde
AU - Viret, Frédéric
AU - Esterni, Benjamin
AU - Genève, Jean
AU - Brain, Etienne
N1 - Funding Information:
Medical writing/editing support was provided by Miller Medical Communications UK and funded by F. Hoffmann-La Roche .
PY - 2011/4/1
Y1 - 2011/4/1
N2 - Objectives: This study investigated the effect of capecitabine-oxaliplatin (XELOX) on functional independence in patients aged ≥ 70 years with histologically proven metastatic colorectal cancer (mCRC). Materials and methods: Patients received capecitabine 750mg/m2 bid d1-14+oxaliplatin 90mg/m2 d1, every 3weeks; doses were increased to 1000 and 120mg/m2, respectively, in the absence of significant toxicity. The primary endpoint was stabilization/improvement of Katz Activities of Daily Living (ADL) scale. Results: Sixty patients were enrolled. ADL was stabilized/improved in 36/40 patients (90%) after 3. cycles, and in 25/27 patients (93%) after 6. cycles. Capecitabine and oxaliplatin doses were increased in 31% of patients. The objective response rate was 37% (1 complete and 21 partial responses). Toxicity included grade 3/4 diarrhea (13%), neurotoxicity (grade 1/2 in 68%, grade 3/4 in 2%), and grade 3/4 anemia (7%). Conclusion: This study demonstrates the feasibility of XELOX in elderly mCRC patients, with no impairment of independence among patients who remained on therapy.
AB - Objectives: This study investigated the effect of capecitabine-oxaliplatin (XELOX) on functional independence in patients aged ≥ 70 years with histologically proven metastatic colorectal cancer (mCRC). Materials and methods: Patients received capecitabine 750mg/m2 bid d1-14+oxaliplatin 90mg/m2 d1, every 3weeks; doses were increased to 1000 and 120mg/m2, respectively, in the absence of significant toxicity. The primary endpoint was stabilization/improvement of Katz Activities of Daily Living (ADL) scale. Results: Sixty patients were enrolled. ADL was stabilized/improved in 36/40 patients (90%) after 3. cycles, and in 25/27 patients (93%) after 6. cycles. Capecitabine and oxaliplatin doses were increased in 31% of patients. The objective response rate was 37% (1 complete and 21 partial responses). Toxicity included grade 3/4 diarrhea (13%), neurotoxicity (grade 1/2 in 68%, grade 3/4 in 2%), and grade 3/4 anemia (7%). Conclusion: This study demonstrates the feasibility of XELOX in elderly mCRC patients, with no impairment of independence among patients who remained on therapy.
KW - Capecitabine
KW - Colorectal cancer
KW - Efficacy
KW - Elderly
KW - Functional independence
KW - Oxaliplatin
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=79952625198&partnerID=8YFLogxK
U2 - 10.1016/j.jgo.2010.11.002
DO - 10.1016/j.jgo.2010.11.002
M3 - Article
AN - SCOPUS:79952625198
SN - 1879-4068
VL - 2
SP - 105
EP - 111
JO - Journal of Geriatric Oncology
JF - Journal of Geriatric Oncology
IS - 2
ER -